摘要
目的探讨人附睾蛋白4与肿瘤相关糖类抗原125(CA125)、肿瘤相关糖类抗原724(CA724)联合测定对卵巢肿瘤的诊断价值。方法应用酶联免疫吸附试验与电化学发光全自动免疫分析仪检测116例卵巢肿瘤患者(其中卵巢癌52例,卵巢良性肿瘤64例)的血清HE4与CA125、CA724,并与健康体检者作对照。结果卵巢癌、卵巢良性肿瘤患者及健康体检者HE4平均水平分别为154.12、58.94、35.25 pmo/lL;阳性率分别为78.8%、3.2%、0%。卵巢癌、卵巢良性肿瘤患者及健康体检者CA125平均水平分别为295.27、29.77、10.28 U/ml;阳性率分别为67.3%、17.2%、1.7%。卵巢癌、卵巢良性肿瘤患者及健康体检者CA724平均水平分别为9.16、3.62、2.73 U/ml;阳性率分别为36.5%、6.3%、3.3%。卵巢癌患者HE4、CA125、CA724的平均值均明显高于卵巢良性肿瘤患者及健康体检者(P<0.001)。HE4、CA125、CA724联合检测卵巢癌、卵巢良性肿瘤患者及健康体检者的阳性率分别为88.5%、54.7%和11.7%。结论 HE4与CA125、CA724联合检测可明显提高卵巢肿瘤诊断的灵敏度,对卵巢肿瘤的早发现、早诊断具有重要的临床意义。
Objective To explore the diagnostic value of the combined detection of human epididymis protein 4（HE4） and cancer antigen 125（CA125） and CA724 for ovarian carcinoma.Methods Serum HE4,CA125 and CA724 of 116 patients with ovarian carcinoma,including 52 cases with ovarian cancer and 64 with benign ovarian tumor,were determined by enzyme-linked immunosorbent assay and full-automatic electrochemistry luminescence immunity analyzer.The detection results were compared with those of the healthy physical examinees.Results The average levels of serum HE4 for the patients with ovarian cancer,for those with benign ovarian tumor,and for the healthy physical examinees were 154.12 pmol/L,58.94 pmol/L and 35.25 pmol/L,and the positive rates were 78.8%,3.2% and 0%,respectively.The average levels of serum CA125 for the patients with ovarian cancer,for the cases with benign ovarian tumor,and for the healthy examinees were 295.27 U/ml,29.77 U/ml and 10.28 U/ml,and the positive rates were 67.3%,17.2% and 1.7%,respectively.The average levels of serum CA724 for the patients with ovarian cancer,for those with benign ovarian tumor and for the healthy examinees were 9.16U/ml,3.62 U/ml and 2.73 U/ml,and the positive rates were 36.5%,6.3% and 3.3%,respectively.The average levels of serum HE4,CA125 and CA724 for the patients with ovarian cancer were significantly higher than those for the patients with benign ovarian tumor and for the healthy examinees（P0.001）.The positive rates of the combined detection serum of HE4,CA125 and CA724 for the patients with ovarian cancer,for those with benign ovarian tumor,and for the healthy examinees were 88.5%,54.7% and 11.7%,respectively.Conclusions The combined detection of serum HE4,CA125 and CA724 can obviously improve the sensitivity of the diagnosis of ovarian carcinoma.It is of great clinical significance in the early discovery and diagnosis of ovarian carcinoma.
出处
《实用预防医学》
CAS
2012年第12期1884-1886,共3页
Practical Preventive Medicine
